Why to invest

Coegin Pharma has set the foundations for an eventful 2021

  • Development of a new ambitious strategy with a focus on skin cancer.
  • Listing on NGM Nordic SME through a reverse takeover by GoldBlue AB.
  • Establishment of the expertise required to conduct clinical trials in actinic keratosis and a future Phase IIa clinical trial in basal cell carcinoma.
  • Established cooperation with Studies&Me and Bispebjerg Hospital for a combined Phase I/II clinical trial in actinic keratosis with AVX001, expected to be conducted and completed in 2021.
  • Submitted clinical application to conduct Phase I/II trial in actinic keratosis.
  • Broadened pipeline and expanded ambitions, including evaluation of projects related to diseases such as leukemia, triple-negative breast cancer and chronic kidney disease.
  • Planned spinouts of two separate subsidiaries focused on systemic cancers and chronic renal disease, respectively.
  • Two completed capital raises totaling MSEK 31.4.